SNZZF (Senzime AB) Cyclically Adjusted Revenue per Share: $0.04 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNZZF Senzime AB SNZZF
56 GF Score
Price $0.47
GF Value $0.98
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Senzime AB Cyclically Adjusted Revenue per Share?

Senzime AB SNZZF 56 Cyclically Adjusted Revenue per Share is $0.04 as of Jun. 2026. GuruFocus rates SNZZF with a GF Score™ of 56/100 and a GF Value™ of $0.98 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Senzime AB's adjusted revenue per share for the three months ended in Jun. 2026 was $0.016. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.04 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Senzime AB's average Cyclically Adjusted Revenue Growth Rate was 28.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 34.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Senzime AB was 34.20% per year. The lowest was 28.10% per year. And the median was 31.15% per year.

As of today (2026-07-22), Senzime AB's current stock price is $0.4735. Senzime AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $0.04. Senzime AB's Cyclically Adjusted PS Ratio of today is 11.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Senzime AB was 277.26. The lowest was 11.94. And the median was 41.01.


Senzime AB  (OTCPK:SNZZF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Senzime AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.4735/0.04
=11.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Senzime AB was 277.26. The lowest was 11.94. And the median was 41.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Senzime AB Cyclically Adjusted Revenue per Share Related Terms


Senzime AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Senzime AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senzime AB Cyclically Adjusted Revenue per Share Chart

Senzime AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.02 0.02 0.03

Senzime AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.04

SNZZF vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Senzime AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senzime AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Senzime AB's Cyclically Adjusted PS Ratio falls into.


SNZZF
56GF Score
Senzime AB SNZZF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senzime AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Senzime AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.016/134.1100*134.1100
=0.016

Current CPI (Jun. 2026) = 134.1100.

Senzime AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.003 101.138 0.004
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.000 103.279 0.000
201712 0.000 103.793 0.000
201803 0.000 103.962 0.000
201806 0.001 104.875 0.001
201809 0.000 105.679 0.000
201812 0.006 105.912 0.008
201903 0.001 105.886 0.001
201906 0.003 106.742 0.004
201909 0.005 107.214 0.006
201912 0.005 107.766 0.006
202003 0.005 106.563 0.006
202006 0.002 107.498 0.002
202009 0.004 107.635 0.005
202012 0.007 108.296 0.009
202103 0.003 108.360 0.004
202106 0.008 108.928 0.010
202109 0.003 110.338 0.004
202112 0.006 112.486 0.007
202203 0.004 114.825 0.005
202206 0.005 118.384 0.006
202209 0.005 122.296 0.005
202212 0.007 126.365 0.007
202303 0.010 127.042 0.011
202306 0.010 129.407 0.010
202309 0.009 130.224 0.009
202312 0.009 131.912 0.009
202403 0.010 132.205 0.010
202406 0.012 132.716 0.012
202409 0.014 132.304 0.014
202412 0.010 132.987 0.010
202503 0.017 132.825 0.017
202506 0.019 133.699 0.019
202509 0.018 133.480 0.018
202512 0.019 133.390 0.019
202603 0.016 133.560 0.016
202606 0.016 134.110 0.016

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.04 mean?
Senzime AB (SNZZF) has a Cyclically Adjusted Revenue per Share of $0.04 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Senzime AB and its competitors.
Is Senzime AB's Cyclically Adjusted Revenue per Share too high?
Senzime AB's current Cyclically Adjusted Revenue per Share is $0.04. Overall, Senzime AB has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Senzime AB's Cyclically Adjusted Revenue per Share of $0.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Senzime AB and its competitors. Senzime AB's current Cyclically Adjusted Revenue per Share is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Based on GuruFocus' analysis, Senzime AB (SNZZF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.98, compared to a current price of $0.47 — trading 51.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.04. Senzime AB's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Senzime AB (SNZZF), the current Cyclically Adjusted Revenue per Share is $0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Senzime AB (SNZZF) Overvalued in 2026?

Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued. The current stock price of $0.47 is trading 51.7% below its estimated GF Value™ of $0.98. GuruFocus considers Senzime AB to be Possible Value Trap.

Key valuation signals for SNZZF:

  • Cyclically Adjusted Revenue per Share: $0.04
  • GF Value™: $0.98 vs. price of $0.47 (51.7% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the SNZZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Senzime AB Business Description

Other Exchanges SEZI:Sweden6YC:Germany
Address Verkstadsgatan 8, hus 1, Uppsala, SWE, 753 23
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
56GF Score

Get the complete analysis for SNZZF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price
$0.98
GF Value